Free Trial
NASDAQ:ZNTL

Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

Zentalis Pharmaceuticals logo
$1.61 -0.05 (-3.01%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$1.62 +0.00 (+0.31%)
As of 10/3/2025 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)

Advanced

Key Stats

Today's Range
$1.60
$1.69
50-Day Range
$1.34
$1.99
52-Week Range
$1.01
$4.44
Volume
739,723 shs
Average Volume
649,711 shs
Market Capitalization
$116.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.84
Consensus Rating
Hold

Company Overview

Zentalis Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

ZNTL MarketRank™: 

Zentalis Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat, and ranked 792nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zentalis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Zentalis Pharmaceuticals has a consensus price target of $5.84, representing about 262.7% upside from its current price of $1.61.

  • Amount of Analyst Coverage

    Zentalis Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Zentalis Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($2.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zentalis Pharmaceuticals is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zentalis Pharmaceuticals is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zentalis Pharmaceuticals has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Zentalis Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.29% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Zentalis Pharmaceuticals has recently increased by 1.34%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Zentalis Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Zentalis Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.29% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Zentalis Pharmaceuticals has recently increased by 1.34%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Zentalis Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for ZNTL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZNTL Stock News Headlines

Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
See More Headlines

ZNTL Stock Analysis - Frequently Asked Questions

Zentalis Pharmaceuticals' stock was trading at $3.03 at the start of the year. Since then, ZNTL shares have decreased by 46.9% and is now trading at $1.61.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) issued its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.19.

Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Home Depot (HD), Chevron (CVX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/06/2025
Today
10/05/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZNTL
CIK
1725160
Fax
N/A
Employees
160
Year Founded
2014

Price Target and Rating

High Price Target
$10.00
Low Price Target
$2.20
Potential Upside/Downside
+262.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$165.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-51.62%
Return on Assets
-40.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.99
Quick Ratio
7.99

Sales & Book Value

Annual Sales
$67.43 million
Price / Sales
1.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.73 per share
Price / Book
0.34

Miscellaneous

Outstanding Shares
72,140,000
Free Float
70,764,000
Market Cap
$116.15 million
Optionable
Optionable
Beta
1.77

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ZNTL) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners